Global Oncology Biosimilars Market, By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Cervical Cancer, Blood Cancer, Others), Drug Class (Monoclonal Antibodies, Granulocyte Colony-Stimulating Factor, Others), Route of Administration (Intravenous, Subcutaneous, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2027
Market Analysis and Insights: Global Oncology Biosimilars Market
Global oncology biosimilars market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.
The growth of oncology biosimilars market enhanced by the growing cases of cancer such as lung cancer and breast cancer, vulnerable aging population and rise in research and development activities conducted by many pharmaceuticals’ companies. In addition, increase patient awareness level, advances in the treatment options and high cost of biologics drugs are some of the impacting factors for the demand of oncology biosimilars. Nevertheless, product recalls coupled with stringent regulations are the factors that hinder the growth of this market.
A biosimilar product describes as biotherapeutics that’s highly similar to the biological product or reference product. Also, biosimilars product has to be no clinically meaningful differences between the two products. The biosimilars which are employed for the treatment of cancer is termed as oncology biosimilars.
Oncology biosimilars market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Oncology Biosimilars Market Scope and Market Size
Oncology biosimilars market is segmented on the basis of indication, drug class, route of administration end-users and distribution channel.
- On the basis of indication, the global oncology biosimilars market is segmented into breast cancer, lung cancer, colorectal cancer, cervical cancer, blood cancer and others.
- Based on drug class, the global oncology biosimilars market is segmented into monoclonal antibodies, granulocyte colony-stimulating factor and others.
- Route of administration segment for global oncology biosimilars market is categorized into intravenous, subcutaneous and others.
- On the basis of end-users, the global oncology biosimilars market is segmented into hospitals, homecare, specialty clinics and others.
- On the basis of distribution channel, the global oncology biosimilars market has been bifurcated into hospital pharmacy, online pharmacy and retail pharmacy.
Global Oncology Biosimilars Market Country Level Analysis
Global oncology biosimilars market is analyzed and market size information is provided by country, indication, drug class, route of administration, end-users and distribution channel as referenced above.
The countries covered in the global oncology biosimilars market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
Based on geography, North America has been witnessing a positive growth for oncology biosimilars market throughout the forecasted period owing to the high prevalence of cancer and increase in number of FDA approval drugs. Europe is considered a second largest growing regional segment due to the key marketed players and increases focuses on the mental health. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Global oncology biosimilars market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Global Oncology Biosimilars Market Share Analysis
Oncology biosimilars market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to global oncology biosimilars market.
The major players covered in the global oncology biosimilars market are Amgen Inc, Pfizer Inc, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd, Allergan, Teva Pharmaceutical Industries Ltd, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Endo International plc, Sun Pharmaceutical Industries Ltd, Mylan N.V., Apotex Inc, Biocad, and others.
Customization Available: Global Oncology Biosimilars Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.